One medicine, a new name
Early development names often stay in the news long after a programme adopts a non-proprietary name. So searches for amycretin and zenagamtide return overlapping studies. The new name marks no separate drug and no launch. To confirm two reports cover the same programme, check the sponsor, the molecule description and the trial identifier.
How zenagamtide differs from CagriSema
Zenagamtide puts GLP-1 and amylin receptor activity into a single molecule. CagriSema combines two components, semaglutide and cagrilintide. Both explore related biological pathways. Their formulation, dosing and evidence differ, so results from one do not transfer to the other. "GLP-1 plus amylin" names a shared scientific theme and covers more than one treatment.
Tablet and injection development
Novo has tested the molecule both by mouth and as an injection under the skin. The way you take a medicine changes absorption, exposure, dose steps and daily use, sometimes by a wide margin. An early oral result proves nothing about the injection, and the reverse holds too. Trial summaries should say which form was studied and keep oral and injected data apart.
Status at the latest review
Novo's current development material lists zenagamtide in phase 3. Scientific materials from 2026 report phase 2 results in type 2 diabetes. These are research stages, with no confirmed UK licence. Phase 2 papers appearing while phase 3 is under way is normal, because publication often lags behind the programme. Use dated sources and ignore the oldest search result.
Reading early weight-loss results
A small study can give an encouraging signal and leave big questions open. Look for the number of participants, treatment length, dose steps, withdrawals due to side effects, and whether the analysis assumes people stayed on treatment. Early studies are not built to settle long-term outcomes or rare risks. Do not set their best figure against a much larger, longer trial of an authorised medicine.
What you can do with this information
The research shows where future treatments may be heading. It gives no reason to buy a research-labelled substance. Taking part properly means joining a regulated clinical trial after an eligibility check. For care now, discuss available options and your practical goals with a clinician. Expect updates when a regulator publishes an authorisation decision or full trial reports change the picture of benefit and risk.
Track trials by their identifier
A trial's registry identifier is a more reliable guide than a headline when a drug changes name. Note the identifier along with the form of the medicine, the population and the date of the source. This helps you tell an oral study from an injection study, and a diabetes programme from an obesity one. You also avoid counting one set of results twice when they appear first under amycretin and later under zenagamtide. A new name or conference talk may cover a trial you have already seen.
Sources
Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.
- Novo Nordisk: current development pipeline novonordisk.com
- Novo Nordisk: zenagamtide phase 2 poster, ADA 2026 sciencehub.novonordisk.com
- Novo Nordisk: obesity development presentation, September 2026 novonordisk.com
Spotted something out of date? Report a mistake.